Back to Archived Journals » International Journal of Interferon, Cytokine and Mediator Research » Volume 3

Potential role of interferon-lambda in the treatment of inflammation and cancer: an update

Authors Dornhoff H, Siebler J, Neurath M

Published 1 July 2011 Volume 2011:3 Pages 51—57


Review by Single anonymous peer review

Peer reviewer comments 3

Heike Dornhoff, Jürgen Siebler, Markus F Neurath
Department of Medicine, University of Nuremberg-Erlangen, Erlangen, Germany

Abstract: The interferon (IFN) family comprises various cytokines with potent responses against RNA and DNA viruses as well as antitumor activities. A recently identified interferon subgroup consists of the so-called lambda interferons with several members, including IFN-λ1, IFN-λ2, and IFN-λ3 (also denoted interleukin [IL]-29, IL28-A, and IL28-B). They represent a newly identified group of the class II cytokine family. While they are functionally related to type I IFNs, they are structurally related to the IL-10 cytokine family. The lambda IFNs signal through a cytokine receptor complex which is unique for IL-28 and IL-29, designated IL-28Rα, and a second chain, the IL-10R2, which is shared with receptors for IL-10 related cytokines such as IL-22 and IL-10. In this review, we summarize recent findings about the relationship between type I and type III IFN signaling as well as their antiviral and antitumor activity. A better understanding of the functional role of IFN-λ in viral infections and immune responses in innate and adaptive immunity opens new therapeutical approaches for the treatment of chronic inflammatory diseases and cancer.

Keywords: interferon, interleukin-28, cancer, viral infections, antiviral, antitumor, immunity

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.